All
Explaining KRAS Mutations For Patients With Colorectal Cancer
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Personalized Kidney Cancer Vaccine May Help Prevent Future Relapse
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
FDA Approval of Calquence Combo Brings Optimism in MCL
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.
The Importance of Utilizing Support Networks Following a Cancer Diagnosis
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine dehydrogenase deficiency.
The Effects of Scanxiety on ‘Normal’ Life
As a cancer survivor, I face added stress with an upcoming black belt test and "scanxiety" before my annual CT scan and oncology appointment.
An Expert Breaks Down What DPD Is and Labeling Updates From The FDA
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.
Lonsurf Shows Survival Benefit Over Placebo in Stage 4 Colorectal Cancer
In patients with residual disease after curative resection of colorectal cancer, Lonsurf showed a numerical improvement in DFS, though not significant.
Pelareorep With Chemo and Tecentriq Shows Acceptable Safety in Metastatic PDAC
Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.
From Patient 3737 to Advocate: The Life-Changing Power of Clinical Trials
Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of cholangiocarcinoma.
Reoperations May Offer Survival Benefit in Recurrent Glioblastoma
When deciding if reoperation is an option in recurrent glioblastoma, factors like tumor location, therapy history and patient health should be considered.
Braftovi Plus Erbitux With mFOLFOX6 May Improve Responses in BRAF V600E+ mCRC
Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.
Tafinlar/Mekinist Combo is Safe, Effective in Patients With Glioma
Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among patients with gliomas.
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events and reduced overall survival.
The Doctors Who Healed Me: My Journey With Colon Cancer and Gratitude
My colon cancer journey showed me how compassionate doctors can change lives, as their kindness and care gave me strength and hope throughout my recovery.
Randy Moss Shares Cancer Update, “Squid Game” Star Dies and More
From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.
Neoadjuvant TKI Prior to Surgery Has Surgical Benefit in Non-Metastatic GIST
Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less invasive or complex surgeries.
Radiotherapy and Temozolomide Improve PFS in IDH-Wildtype Glioblastoma
Concomitant radiotherapy plus temozolomide significantly increased progression-free survival versus radiotherapy alone in IDH-wildtype glioblastoma.
Lumakras Combo May Replace SOC in Third-Line Treatment for mCRC
Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated metastatic colorectal cancer.
How a Cancer Diagnosis Wiped That Smug Look Off My Face
It took a nightmare about a second cancer to shake me out of my complacency, and I nearly called 9 1 1.
Opdivo Plus Chemo May Be Effective and Safe in Older Patients with cHL
Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.
Krazati and Erbitux Effective for KRAS G12C-Mutant Advanced mCRC
Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer.
Erleada Combo Shows Comparable Quality of Life Outcomes in Prostate Cancer
A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor approved for first line therapy.
You Need Tough Skin With Cancer
Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis diagnosis.
Welireg With Cabometyx Elicits Promising First-Line Responses in ccRCC
Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear-cell renal cell carcinoma.
Palliative Care May Reduce Invasive Intervention Use in Early-Onset CRC
Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.
Circulating Tumor DNA May Have Prognostic Value in Kidney Cancer
Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.
Pancreatic Cancer Diagnoses and Mortality Rates Rise
The recent American Cancer Society’s Cancer Statistics, 2025 report was released revealing a sobering trend for pancreatic cancer.
